Selected markers of endothelial dysfunction in women with polycystic ovary syndrome

Endokrynologia Polska

Volumn 62, Issue 3, 2011, Pages 243-248

  Foltyn, Wanda ^a   Strzelczyk, Janusz ^a   Marek, Bogan ^a   Kajdaniuk, Dariusz ^a   Siemińska, Lucyna ^a   Zemczak, Anna ^a   Blicharz Dorniak, Jolanta ^a   Kos Kudła, Beata ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

E selectin; Endothelin 1; Endothelium; Polycystic ovary syndrome; Von Willebrand factor

Indexed keywords

CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; OVARY POLYCYSTIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; E-SELECTIN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; VON WILLEBRAND FACTOR;

EID: 79960761385     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bickerton ST, Clark N, Meeking D et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58: 151-154. (Pubitemid 40193799)
2. Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 2008; 26: 39-44.
3. Cussons AJ, Stuckley BG, Watss GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006; 185: 227-239.
4. Predos P: Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 2002; 21: 109-116.
5. Chong, Blann AD and Lip GYH. Assessment of endothelial damage and dysfunction: observations in relation to heart failure. Q J Med 2003; 96: 253-267. (Pubitemid 36432385)
6. Abdu TA, Elhadd T, Pfeifer M et al. Endothelial dysfunction in endocrine disease. Trends Endocrinol Metab 2001; 12: 257-265.
7. Roldan V, Marin F, Lip GYH. et al. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003; 90: 1007-1020. (Pubitemid 38004418)
8. Teplyakov AI. Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis. J Cardiovasc Pharmacol 2004; 44 (Suppl 1): S274-S275. (Pubitemid 40039694)
9. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006; 368: 33-47. (Pubitemid 43792418)
10. Lip GYH, Blann AD. Von Willebrand Factor: a marker of endothelial dysfunction in vascular disorders? Cardiovas Res 1997; 34: 255-265.
11. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-993. (Pubitemid 30397600)
12. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-586. (Pubitemid 28376967)
13. Bickerton ST, Clark N, Meeking D et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005; 58: 151-154. (Pubitemid 40193799)
14. Diamanti-Kandarakis E, Peterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reproduction 2006; 21: 1426-1431. (Pubitemid 44445017)
15. Villuendas G, San Milan JM, Sancho J et al. The 597G A and 174 G C polymorphisms in the promotor of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 1134-1141. (Pubitemid 36121078)
16. Escobar-Morreale HF, Calvo RM, Sancho J et al. TNF-alfa and hyperandrogenism: a clinical, biochemical and molecular genetic study. J Clin Endocrinol Metab 2001; 86: 3761-3767.
17. Pirwany IR, Fleming R, Greer IA et al. Lipids and lipoprotein subtractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54: 447-453. (Pubitemid 34204180)
18. Valkenburg O, Steegers-Theunissen RP, Smedts HP et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93: 470-476. (Pubitemid 351240818)
19. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
20. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800. (Pubitemid 28009567)
21. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003; 88: 1927-1932. (Pubitemid 36549858)
22. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab 2003; 14: 365-370.
23. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
24. Mombouli JV, VanHoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
25. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60. (Pubitemid 29078218)
26. Diamanti-Kandarakis E, Peterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reproduction 2006; 21: 1426-143.
27. Diamanti-Kandarakis E, Spina G, Kouli C et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86: 4666-4673. (Pubitemid 33020504)
28. Orio F, Jr, Palomba S, Cascella T et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 4588-4593. (Pubitemid 39244474)
29. Van Rooijen M, Hansson LO, Frostega RD et al. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost 2006; 4: 77-82.
30. Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives. Fertility and Sterility 2002; 77: 919-927. (Pubitemid 34497157)
31. Norman RJ, Dewailly D, Legro RS et al. Polycystic ovary syndrome. Lancet 2007; 370: 685-697. (Pubitemid 47285318)
32. Shaw LJ, Bairey Merz CN, Azziz R et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival. results from the National Institutes of Health - National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-1284. (Pubitemid 351519721)
33. Wild S, Pierpoint T, McKeigue P et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600. (Pubitemid 30337085)